Preclinical Modeling of Tumor Growth and Angiogenesis Inhibition to Describe Pazopanib Clinical Effects in Renal Cell Carcinoma

Publisher： John Wiley & Sons Inc

E-ISSN： 2163-8306|4|11|660-668

ISSN： 2163-8306

Source： Cpt: Pharmacometrics & Systems Pharmacology, Vol.4, Iss.11, 2015-11, pp. : 660-668

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Targeting angiogenesis in renal cell carcinoma

By Posadas Edwin M   Limvorasak Suwicha   Sharma Shaleekha   Figlin Robert A  

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 16, 2013-11 ,pp. : 2221-2236

Informa Healthcare

Access to resources Recommend Favorite

Targeting Angiogenesis in Renal Cell Carcinoma

By  

Current Cancer Drug Targets, Vol. 8, Iss. 5, 2008-08 ,pp. : 349-358

Bentham Science Publishers

Access to resources Recommend Favorite

Pazopanib in Renal Cell Carcinoma Dialysis Patients: A Mini-Review and a Case Report

By  

Current Drug Targets, Vol. 17, Iss. 15, 2016-12 ,pp. : 1755-1760

Bentham Science Publishers

Access to resources Recommend Favorite

Tumor Cell-Based Vaccination in Renal Cell Carcinoma: Rationale,Approaches, and Recent Clinical Development

By  

Current Drug Targets, Vol. 3, Iss. 5, 2002-10 ,pp. : 401-408

Bentham Science Publishers

Access to resources Recommend Favorite

Pazopanib: The Newest Tyrosine Kinase Inhibitor for the Treatment of Advanced or Metastatic Renal Cell Carcinoma

By Keisner Sidney V.   Shah Sachin R.  

Drugs, Vol. 71, Iss. 4, 2011-03 ,pp. : 443-454

Adis International

Access to resources Recommend Favorite